Gilead HCV Sales Plateau, But Maintain Dominant Market Share
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. continues to bring in blockbuster revenues on sofosbuvir-based hepatitis C regimens and to maintain a dominant market share in that space, but HCV product sales leveled off from the second quarter due to several factors, the company reported during its third quarter earnings call on Oct. 27.
You may also be interested in...
Antios Raises $96m To Advance HBV Drug With Pharmasset Pedigree
Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian
Still a clinical-stage company, Viking is studying promising candidates for both obesity and MASH in Phase II, but may need to prioritize one while partnering the other.